Philikos Overview
- Year Founded
-
2023
- Status
-
Private
- Employees
-
1
- Latest Deal Type
-
Early Stage VC
- Investors
-
2
Philikos General Information
Description
Developer of antibody-based therapies designed to treat severe immune disorders. The company platform offers a compound, T-Guard, which rebalances the immune system by depleting activated T cells and NK cells, enabling patients with conditions like scleroderma to achieve restored immune function and improved long-term health outcomes.
Contact Information
Website
www.philikos.comCorporate Office
- Molenveldlaan 100
- 6523 RN Nijmegen
- Netherlands
Corporate Office
- Molenveldlaan 100
- 6523 RN Nijmegen
- Netherlands
Philikos Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC | 23-Dec-2024 | Completed | Generating Revenue |
Philikos Signals
Philikos Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Oost NL | Venture Capital | Minority | ||
| Radboud University | University | Minority |
Philikos FAQs
-
When was Philikos founded?
Philikos was founded in 2023.
-
Where is Philikos headquartered?
Philikos is headquartered in Nijmegen, Netherlands.
-
What is the size of Philikos?
Philikos has 1 total employees.
-
What industry is Philikos in?
Philikos’s primary industry is Drug Discovery.
-
Is Philikos a private or public company?
Philikos is a Private company.
-
What is Philikos’s current revenue?
The current revenue for Philikos is .
-
Who are Philikos’s investors?
Oost NL and Radboud University have invested in Philikos.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process